Domača stranMEHCQ • OTCMKTS
add
23andMe Holding Co
Prejšnji trg. dan.
4,24 $
Dnevni razpon
4,05 $ - 4,39 $
Letni razpon
0,47 $ - 10,81 $
Tržna kapitalizacija
117,60 mio. USD
Povprečni obseg
575,71 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
OTCMKTS
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
(USD) | mar. 2025info | Sprememba L/L |
---|---|---|
Prihodek | 45,15 mio. | −29,49 % |
Stroški poslovanja | 65,51 mio. | −34,62 % |
Čisti dohodek | −99,35 mio. | 52,43 % |
Čista dobičkovnost prihodkov | −220,04 | 32,54 % |
Earnings per share | — | — |
EBITDA | −45,06 mio. | 35,08 % |
Efektivna davčna stopnja | 0,00 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
(USD) | mar. 2025info | Sprememba L/L |
---|---|---|
Denar. in kratkor. naložbe | 38,25 mio. | −82,33 % |
Skupna sredstva | 159,89 mio. | −59,54 % |
Skupne obveznosti | 186,64 mio. | −9,68 % |
Celoten lastniški kapital | −26,74 mio. | — |
Shares outstanding | 27,54 mio. | — |
Razmerje P/B | −4,37 | — |
Donosnost sredstev | −54,88 % | — |
Donosnost kapitala | −230,70 % | — |
Denarni tok
Neto sprememba denarnih sredstev
(USD) | mar. 2025info | Sprememba L/L |
---|---|---|
Čisti dohodek | −99,35 mio. | 52,43 % |
Denar iz dejavnosti | −40,73 mio. | −57,97 % |
Denar iz naložb | −734,00 tis. | 65,80 % |
Denar iz financiranja | −529,00 tis. | −126,45 % |
Neto sprememba denarnih sredstev | −41,99 mio. | −61,95 % |
Prost denarni tok | −82,91 mio. | −285,64 % |
Vizitka
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.
The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. Wikipedia
Datum ustanovitve
apr. 2006
Sedež organizacije
Spletno mesto
Zaposleni
261